Personalis Other Share Holders Equity 2018-2024 | PSNL

Personalis other share holders equity from 2018 to 2024. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Personalis Annual Other Share Holders Equity
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $0
Personalis Quarterly Other Share Holders Equity
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31 $0
2018-12-31
2018-09-30 $0
2018-06-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.305B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.837B 6.73
Dr Reddy's Laboratories (RDY) India $13.111B 19.64
BridgeBio Pharma (BBIO) United States $5.028B 0.00
Bausch Health Cos (BHC) Canada $2.902B 2.19
Amphastar Pharmaceuticals (AMPH) United States $2.394B 13.40
Supernus Pharmaceuticals (SUPN) United States $1.753B 353.56
Taysha Gene Therapies (TSHA) United States $0.441B 71.67
Assembly Biosciences (ASMB) United States $0.123B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00